ArticlePlastic and reconstructive surgery. Global open2025
Bleeding, Drains, and Reoperation in Transmasculine Chest Surgery: What 2,534 Patients Tell Us About Tranexamic Acid.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematoma, seroma, and unplanned reoperation are the most frequent early complications after gender-affirming mastectomy with hematoma being the most common complication and the most common reason for reoperation. Tranexamic acid (TXA) is increasingly incorporated into enhanced-recovery protocols, yet its route-specific benefits remain unclear. Methods: In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases were searched for comparative studies of TXA versus no TXA in transmasculine chest surgery. Review Manager 5.4 was used for statistical analysis. Results: Seven retrospective cohorts (2534 patients) met the inclusion criteria. Overall, TXA significantly reduced hematoma risk by 41% (relative risk reduction [RRR] = 41%; risk ratio [RR] = 0.59, 95% confidence interval: 0.41-0.83; Conclusions: IV TXA safely reduces risks of hematoma, seroma, and reoperation after gender-affirming mastectomy, without increasing venous thromboembolism risk. Topical TXA confers no measurable advantage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.